atorvastatin has been researched along with ramipril in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bugiardini, R; Fontana, F; Manfrini, O; Pizzi, C | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| George, M; Joseph, L; Rao B, VR | 1 |
| Brown, SL; Jenrow, KA; Kim, JH; Kolozsvary, A; Lapanowski, K; Liu, J | 1 |
| Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR | 1 |
| Sankar, AS; Venkappaya, D; Vetrichelvan, T | 1 |
| AlBacha, Jd; Azar, A; Fajloun, Z; Haddad, K; Hamoui, S; Khoury, M; Makdissy, N; Mouawad, C | 1 |
| Barrios, V; Escobar, C | 1 |
| Castellano, JM; Fuster, V; Tamargo, J | 1 |
| Einecke, D | 1 |
| Abarca, B; González-Juanatey, JR; Llisterri, JL; Lobos, JM; Mostaza, JM | 1 |
| Stiefelhagen, P | 1 |
| Barrios, V; Castellano, JM; Cosin-Sales, J; Fuster, V; Gracia, A; Kaskens, L; Ruiz, JE; Zsolt, I | 1 |
| Abarca, B; Alemán, JJ; Baron-Esquivias, G; Egocheaga, I; Galve, E; Garcia-Moll, FX; González-Juanatey, JR; Lidón, RM; Llisterri, JL; Lobos, JM; Millán, J; Mostaza, JM; Pallares, V; Sánchez, PL; Suárez, C | 1 |
| Dunphy, L; Morhij, R; Tucker, S | 1 |
| González-Juanatey, JR | 1 |
| Chouksey, D; Dani, R; Dube, M; Dubey, A | 1 |
| González-Juanatey, JR; Oudovenko, N; Tamargo, J; Torres, F; Weisser, B | 1 |
| Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R | 1 |
| Gundlach, K; Hermann, R; Seiler, D | 1 |
| Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D | 1 |
| Abdallah, NA; El-Awady, MI; El-Brashy, AM; Ibrahim, FA | 1 |
3 review(s) available for atorvastatin and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Improving cardiovascular protection: focus on a cardiovascular polypill.
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Platelet Aggregation Inhibitors; Ramipril; Simvastatin | 2016 |
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2015 |
4 trial(s) available for atorvastatin and ramipril
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Brachial Artery; Drug Therapy, Combination; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microvascular Angina; Middle Aged; Oxidative Stress; Pyrroles; Ramipril; Sickness Impact Profile; Superoxide Dismutase; Vasodilation | 2004 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
Topics: Aspirin; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ramipril; Treatment Outcome | 2021 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Secondary Prevention | 2022 |
19 other study(ies) available for atorvastatin and ramipril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Capsules; Chromatography, High Pressure Liquid; Drug Combinations; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Pyrroles; Ramipril; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2008 |
Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Atorvastatin; Cesium Radioisotopes; Cranial Irradiation; Dentate Gyrus; Heptanoic Acids; Immunoenzyme Techniques; Male; Neurogenesis; Pyrroles; Radiation Injuries, Experimental; Ramipril; Rats; Rats, Inbred F344 | 2011 |
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Chromatography, Liquid; Drug Stability; Heptanoic Acids; Humans; Least-Squares Analysis; Male; Nevirapine; Pyrroles; Ramipril; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Simultaneous estimation of ramipril, acetylsalicylic acid and atorvastatin calcium by chemometrics assisted UV-spectrophotometric method in capsules.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calibration; Capsules; Chemistry, Pharmaceutical; Heptanoic Acids; Humans; Least-Squares Analysis; Models, Theoretical; Pyrroles; Ramipril; Regression Analysis; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2011 |
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cytokines; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lebanon; Male; Middle Aged; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Polymorphism, Single Nucleotide; Ramipril; Treatment Outcome; Young Adult | 2015 |
[Polypill for secondary coronary heart disease prevention].
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medication Adherence; Ramipril | 2015 |
A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Europe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ramipril; Secondary Prevention; Spain | 2016 |
[Combination drug improves adherence].
Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2016 |
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Markov Chains; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ramipril; Retrospective Studies; Secondary Prevention; Spain | 2017 |
Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Medication Adherence; Ramipril; Salicylic Acid; Secondary Prevention | 2017 |
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Compartment Syndromes; Exercise; Fasciotomy; Humans; Male; Middle Aged; Pain; Postoperative Complications; Ramipril; Rhabdomyolysis; Thigh | 2017 |
Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Consensus; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ramipril; Secondary Prevention | 2018 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Brain; Brain Ischemia; Cranial Nerve Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Middle Aged; Paresis; Physical Therapy Modalities; Platelet Aggregation Inhibitors; Ramipril; Stroke; Syndrome | 2019 |
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cerebrovascular Disorders; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Recurrence; Retrospective Studies; Secondary Prevention; Tablets; Tertiary Care Centers; Time Factors; Treatment Outcome | 2020 |
Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin.
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biological Availability; Drug Combinations; Drug Interactions; Gastrointestinal Motility; Healthy Volunteers; Humans; Intestinal Absorption; Male; Ramipril; Young Adult | 2021 |
Multicomponent spectrophotometric determination of a ternary mixture of widely-prescribed cardiovascular drugs by four different methods.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Humans; Ramipril; Spectrophotometry | 2023 |